
Ascentage Pharma Group International: financial statements
Price
$11.97
November 20, 2026Market cap $1.1B
What Ploutos Investor adds for Ascentage Pharma Group International
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Revenue
+62.0% a year over 2 years
| Line | 2023 | 2024 | 2025 | Average a year |
|---|---|---|---|---|
| Revenue | $31M | $134M | $82M | +62.0% |
| Cost of revenue | $4.3M | $4.0M | $7.0M | +27.5% |
| Gross profit | $27M | $130M | $75M | +66.8% |
| Operating income | -$131M | -$54M | -$177M | |
| Net income | -$130M | -$56M | -$178M | |
| Earnings per share | -$1.85 | -$0.73 | -$2.00 | |
| Earnings per share, basic | -$1.85 | -$0.73 | -$2.00 | |
| Margins | ||||
| Gross margin | 86.2% | 97.0% | 91.5% | |
| Operating margin | -420.2% | -40.3% | -215.3% | |
| Net margin | -417.0% | -41.3% | -216.5% | |
Financial statements
AAPG's revenue, profits and cash flows from 2022 to 2022, 1 more fiscal year
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 4 fiscal years.
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
Per-share figures are per quoted ADS, which stands for 4 of the company's ordinary shares; the filings count per ordinary share.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
Goodwill by segment
Dec 31, 2025Total goodwill
$25M
The company does not state its goodwill by segment, at December 31, 2025. The filing
Goodwill by year
The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.
The full analysis
What do Ascentage Pharma Group International's filings show?
These are Ascentage Pharma Group International's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much revenue did AAPG have in 2025?
Ascentage Pharma Group International had revenue of $82M and net income of -$178M in fiscal 2025, a net margin of -216.5%.
How much free cash flow does AAPG have?
In fiscal 2025 Ascentage Pharma Group International had cash from operations of -$168M and spent $3.9M on capital expenditure, leaving -$172M of free cash flow.
Where are the figures from?
From Ascentage Pharma Group International's annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.